Rewarming following hypothermic cardiopulmonary bypass in the malignant hyperthermia-susceptible patient: implications for diagnosis and perioperative management
- PMID: 2914339
- DOI: 10.1007/BF03010893
Rewarming following hypothermic cardiopulmonary bypass in the malignant hyperthermia-susceptible patient: implications for diagnosis and perioperative management
Abstract
A 55-year-old, malignant hyperthermia-susceptible patient underwent myocardial revascularization without incident. Six hours postoperatively, he developed what was initially diagnosed as an MH crisis, for which he received intravenous dantrolene. The resultant muscle weakness prolonged the duration of postoperative mechanical ventilation and likely contributed to the development of a postoperative pneumonia. Plasma dantrolene levels were measured for the first 48 hours postoperatively and correlated with clinical findings. On reviewing the patient's perioperative course, it was felt that the hypermetabolic state was not due to MH. The patient's pattern of rewarming following hypothermic cardiopulmonary bypass was similar to non-MH-susceptible patients. Because of the difficulty in diagnosing a MH crisis after hypothermic bypass, it is recommended that patients receive prophylactic dantrolene preoperatively and after bypass. Nondepolarizing muscle relaxants should be given postoperatively to prevent shivering and respiratory acidosis while patients rewarm.
Similar articles
-
Malignant hyperthermia following systemic rewarming after hypothermic cardiopulmonary bypass.Anesth Analg. 2006 Feb;102(2):372-5. doi: 10.1213/01.ane.0000189596.70694.36. Anesth Analg. 2006. PMID: 16428525
-
Sevoflurane-induced malignant hyperthermia during cardiopulmonary bypass and moderate hypothermia.Acta Anaesthesiol Scand. 2004 Sep;48(8):1062-5. doi: 10.1111/j.0001-5172.2004.00451.x. Acta Anaesthesiol Scand. 2004. PMID: 15315628
-
Can we prevent malignant hyperthermia after hypothermic cardiopulmonary bypass in a malignant hyperthermia-susceptible patient?Anesth Analg. 2007 Jan;104(1):214; author reply 214-5. doi: 10.1213/01.ane.0000249792.37338.cc. Anesth Analg. 2007. PMID: 17179280 No abstract available.
-
Malignant hyperthermia susceptibility: anaesthetic implications and risk stratification.QJM. 1997 Jan;90(1):13-8. doi: 10.1093/qjmed/90.1.13. QJM. 1997. PMID: 9093584 Review.
-
[An attempt to reconcile differences of opinion in the field of malignant hyperthermia].Anasthesiol Intensivmed Notfallmed Schmerzther. 1991 Dec;26(8):464-7. doi: 10.1055/s-2007-1000617. Anasthesiol Intensivmed Notfallmed Schmerzther. 1991. PMID: 1786307 Review. German.
Cited by
-
Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States.Anesth Analg. 2011 May;112(5):1115-23. doi: 10.1213/ANE.0b013e31820b5f1f. Epub 2011 Mar 3. Anesth Analg. 2011. PMID: 21372281 Free PMC article.
-
Malignant Hyperthermia: Report of Two Cases with a Neglected Complication in Cardiac Surgery.J Tehran Heart Cent. 2017 Oct;12(4):175-183. J Tehran Heart Cent. 2017. PMID: 29576786 Free PMC article.
-
Successful management of hypothermic cardiopulmonary bypass in a malignant hyperthermia susceptible patient.Ann Card Anaesth. 2020 Jul-Sep;23(3):367-371. doi: 10.4103/aca.ACA_245_18. Ann Card Anaesth. 2020. PMID: 32687103 Free PMC article.
-
Hyperthermia after cardiopulmonary bypass in a child.Can J Anaesth. 1992 Jan;39(1):99-100. doi: 10.1007/BF03008693. Can J Anaesth. 1992. PMID: 1733547 No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources